{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-094869","form_type":"8-K","ticker":"AVBP","cik":"0001868279","company_name":"ArriVent BioPharma, Inc.","filed_at":"2026-08-12T20:07:37+00:00","discovered_at":"2026-08-12T20:09:07.487133+00:00","generated_at":"2026-08-12T20:09:41.406045+00:00","sec_items":["1.01","2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ArriVent reports H1 results and licenses ARR-002 to Allist for up to $80.6M","bullets":["Entered exclusive license with Allist for ARR-002 in Greater China; potential $80.6M in upfront, milestones, plus tiered royalties (mid-single to low-double digit).","Cash and investments $373.1M at June 30, 2026; expected to fund operations into 2028.","Net loss $93.2M for H1 2026 vs $95.8M in H1 2025; R&D $80.0M, G&A $18.8M.","Firmonertinib Phase 3 FURVENT topline data for EGFR exon20 NSCLC expected 2H 2026.","ARR-002 first patient dosing expected Q3 2026; ARR-217 advanced to Phase 1b dose optimization."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-094869","json":"https://secwatch.observer/filing/0001104659-26-094869.json","markdown":"https://secwatch.observer/filing/0001104659-26-094869.md","text":"https://secwatch.observer/filing/0001104659-26-094869.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1868279/000110465926094869/0001104659-26-094869-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1868279/000110465926094869/tm2622880d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-12T20:09:41.406045+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}